Last reviewed · How we verify
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients With Reduced Ejection Infarction
This is a multicenter, randomized, double-blind, placebo-controlled study including patients with ejection fraction decreased heart failure under standardized treatment, to evaluate QiShenYiQi (QSYQ) dropping pill's curative effect in reducing cardiovascular death and heart failure rehospitalization compared with placebo.
Details
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 5380 |
| Start date | 2019-03-26 |
| Completion | 2021-09 |
Conditions
- Heart Failure
Interventions
- Qishenyiqi dropping pills
- Placebo
Primary outcomes
- Time to the occurrence of cardiovascular (CV) death or heart failure (HF) re-hospitalization. — up to 30 months
Compared with placebo, whether QSYQ prolong the occurrence of CV death or HF re-hospitalization of patients with chronic heart failure with lower ejection fraction (HFrEF). The treatment arm with the delayed events happening will be deemed as having a successful response.
Countries
China